TYY-31
TYY-31 is an orally active, selective S1PR1 agonist with an EC50 of 1.13 pM. TYY-31 promotes the phosphorylation of ERK1/2. TYY-31 exerts anti-inflammatory and immunosuppressive effects, ameliorates DSS-induced colitis in mice, and reduces peripheral blood lymphocyte counts in mice in a dose-dependent manner. TYY-31 can be used for the research of ulcerative colitis.
For research use only. We do not sell to patients.
- Formula: C27H26FN5O3
- Molecular Weight:487.53
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
S1PR1 1.13 pM (EC50) |
In Vitro
TYY-31 is a highly selective S1PR1 agonist in Tango CHO cells, with single-digit picomolar potency against S1PR1, exhibiting over 106-fold selectivity over S1PR2, S1PR3 and S1PR5, and over 30000-fold selectivity over S1PR4[1].
TYY-31 (treated at 10 μM for 1.5 h followed by a 20 h recovery) potently induces S1PR1 internalization in HEK293T cells stably expressing S1PR1, with an EC50 of 0.73 nM[1].
TYY-31 (1-1000 nM) activates ERK1/2 phosphorylation in a concentration-dependent manner in S1PR1-expressing cells, indicating that it activates the downstream signaling pathway of S1PR1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | Cmax | Tmax | AUC0-t | T1/2 | CL | Vss | F |
|---|---|---|---|---|---|---|---|---|---|
| Rat[1] | 1 mg/kg | i.v. | 198.6 ng/mL | 0.08 h | 181.1 ng·h/mL | 1.54 h | 99.77 mL/min/kg | 8.84 L/kg | / |
| Rat[1] | 10 mg/kg | p.o. | 374.9 ng/mL | 2.67 h | 2221 ng·h/mL | 3.61 h | 59.35 mL/min/kg | / | 122.6 % |
| Mice[1] | 1 mg/kg | i.v. | 390.0 ng/mL | 0.08 h | 364.8 ng·h/mL | 1.30 h | 45.84 mL/min/kg | 4.07 L/kg | / |
| Mice[1] | 1 mg/kg | p.o. | 130.8 ng/mL | 0.50 h | 235.0 ng·h/mL | 2.86 h | 59.17 mL/min/kg | / | 76.40 % |
In Vivo
TYY-31 (0.1-1 mg/kg; p.o.; once daily; for 7 consecutive days) effectively ameliorates DSS-induced colitis in mice even at doses as low as 0.1 mg/kg, with the ameliorative effect at the 0.3 mg/kg dose being comparable to that of Ozanimod (HY-12288)[1].
TYY-31 (5 μM; environmental exposure; medium replaced daily) potently inhibits the expression of key pro-inflammatory mediators in dextran sulfate sodium (DSS)-induced intestinal inflammation of zebrafish (Danio rerio), and exhibits better efficacy than Ozanimod at the same concentration[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR (male, 18−20 g)[1]
-
Dosage:0.1 mg/kg; 0.3 mg/kg; 1 mg/kg
-
Administration:p.o.; single dose
-
Result:Induced a dose-dependent reduction in peripheral blood lymphocyte counts.
Significantly reduced lymphocyte counts at 3 hours postadministration in mice treated with 0.3 mg/kg and 1 mg/kg.
Substantially recovered lymphocyte counts to near baseline levels by 24 hours postadministration across all doses.
-
Animal Model:unspecified (6 per group, DSS-induced colitis model)[1]
-
Dosage:0.1 mg/kg; 0.3 mg/kg; 1 mg/kg
-
Administration:p.o.; daily; 7 days
-
Result:Dose-dependently mitigated DSS-induced weight loss, with 0.3 mg/kg and 1 mg/kg doses showing body weight recovery comparable to Ozanimod (1 mg/kg).
Significantly reduced DAI scores from day 9 onward across all doses, with 0.1 mg/kg and 0.3 mg/kg demonstrating efficacy comparable to Ozanimod (1 mg/kg).
Promoted significant recovery of colon length across all doses, including the low 0.1 mg/kg dose.
Maintained near-intact mucosal architecture with only focal ulcerations in treated mice, in contrast to the model group's severe inflammation, crypt loss, and epithelial damage.
-
Animal Model:larvae (4 days postfertilization)[1]
-
Dosage:5 μM
-
Administration:environmental exposure; daily medium renewal
-
Result:Significantly suppressed DSS-induced upregulation of IL-1β, IL-8, MMP9, and TNF-α mRNA expression.
Exhibited more pronounced inhibitory effect on pro-inflammatory biomarkers than Ozanimod at the same 5 μM concentration.
Chemical Information
-
Molecular Weight 487.53
-
Formula C27H26FN5O3
-
SMILES
CC1=C(C2=NC=C(N=C2)F)C=CC(C3=NC(C4=CC=C(C(CC)=C4)CN[C@@H]5C[C@@H](C5)C(O)=O)=NO3)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)